MiNK Therapeutics, Inc. (INKT) News
Follow MiNK Therapeutics, Inc. (INKT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
MiNK Therapeutics to Report Third-Quarter 2026 Results
EQUITY | Nov 02, 2026, 09:39 PM UTC
L
MiNK Therapeutics (INKT) Selected for ARPA-H BoSS Initiative
MiNK Therapeutics was selected as a therapeutic cell platform for an ARPA-H BoSS team aiming to enable room—temperature cell therapy storage; ARPA-H has committed up to $87M across the four-year program.Material DetailsC
NEWS | Sep 30, 2026, 12:01 PM UTC
L
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperatureARPA-H has committed up to $87 million a
NEWS | Sep 30, 2026, 12:01 PM UTC
L
MiNK Therapeutics opens randomized phase 2 Agent 797 study
MiNK Therapeutics says it moved Agent 797 into a randomized phase 2 study for acute lung injury and ARDS and reported narrowed net loss of $3.1 million with cash and equivalents of $8.8 million.
EARNINGS | Aug 13, 2026, 01:29 PM UTC
L
MiNK Therapeutics (INKT) reports Q2 2026 results; Phase 2 agenT-797 observations
MiNK Therapeutics (INKT) reports second-quarter 2026 financial results and observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
M
MiNK Therapeutics Presents Phase 2 Trial Observations
MiNK Therapeutics shares early Phase 2 trial results
EQUITY | Aug 06, 2026, 04:00 PM UTC
L
INKT - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highligh
INKT - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
EARNINGS | Aug 06, 2026, 12:19 PM UTC